M2 PHARMA-February 7, 2012-Acorda Therapeutics Inc unveils authorised generic ZANAFLEX
CAPSULES for the management of spasticity(C)2012 M2 COMMUNICATIONS
For some years doctors have prescribed it "off-label" for certain kinds of MS-related urinary incontinence and as a second-line treatment for upper extremity spasticity when first-line medications, such as Lioresal (baclofen) and Zanaflex
(tizanidine), were not effective.
Tizanidine, marketed as Zanaflex
by Acorda Therapeutics, is a centrally acting [[alpha].
The capsule form of the drug is a new formulation of Elan's currently marketed Zanaflex
Generics approvals have also been made for the equivalents of Axid and Zanaflex
The litigation was initiated in 2007, based on Apotex Inc's submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) seeking marketing approval for generic versions of three dosage strengths of Zanaflex
Capsules (tizanidine hydrochloride).
(tizanidine hydrochloride) is an oral drug which reduces MS-related spasticity without reducing muscle strength.
Multicenter trials of Zanaflex
, completed in the U.